Table 4 Univariate and multivariate analysis. Signifcant values are in bold.

Gender

Male (reference)

–

1

–

–

Female

0.931

0.963 (0.415, 2.236)

–

–

Age

<65 (reference)

–

1

–

–

≥ 65

0.463

0.762 (0.369, 1.575)

–

–

Smoking history

No (reference)

–

1

–

–

Yes

0.752

0.889 (0.429, 1.844)

–

–

Unclear

0.404

0.526 (0.116, 2.380)

–

–

Pathological type

Adenocarcinoma of lung (reference)

–

1

–

–

Squamous cell lung carcinoma

0.229

0.650 (0.322, 1.311)

–

–

PD-L1

<1% (reference)

–

1

–

–

≥ 1, <50

0.340

1.784 (0.543, 5.858)

–

–

≥ 50

0.828

0.845 (0.185, 3.861)

–

–

Unclear

0.491

1.467 (0.493, 4.368)

–

–

EGFR

Wild-type(reference)

–

1

–

–

Mutant-type

0.900

0.931 (0.302, 2.869)

–

–

Unclear

0.389

1.381 (0.662, 2.879)

–

–

Interval therapy

No (reference)

–

1

–

–

Yes

0.084

1.936 (0.914, 4.101)

–

–

Therapeutic regimen

ICIs (reference)

–

1

–

1

Chemo-ICIs

0.018

0.290 (0.104, 0.810)

0.040

0.336 (0.119, 0.952)

ICIs + targeted therapy

0.027

0.308 (0.108, 0.876)

0.050

0.350 (0.122, 1.000)

Chemo-ICIs + targeted therapy

0.044

0.110 (0.013, 0.941)

0.060

0.126 (0.015, 1.088)

Immunotherapy model

Original immune drugs

–

1

–

–

New immune drugs

0.785

0.907 (0.450, 1.827)

–

–

Resistant form

Primary resistance

–

1

–

1

Secondary resistance

0.028

0.453 (0.223, 0.918)

0.051

0.495 (0.244, 1.004)